Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396453 | 1.00 | LCK (0.48) | LCKCHRNA7MAPK1GABRPGABRD | |
| SCHEMBL844263 | 0.88 | LCK (0.51) | LCKCHRNA7MAPK1GABRPGABRD | |
| SCHEMBL18593512 | 0.81 | CHRNA7 (0.52) | CHRNA7KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL843122 | 0.80 | CHRNA7 (0.47) | CHRNA7KDM4EALDH1A1MAPT | |
| SCHEMBL1208246 | 0.79 | CHRNA7 (0.52) | LCKCHRNA7MAPK1ALDH1A1LMNA | |
| SCHEMBL21889140 | 0.76 | CHRNA7 (0.41) | CHRNA7KDM4EDYRK1ANTRK1HTR3A | |
| SCHEMBL1219368 | 0.74 | CHRNA7 (0.48) | CHRNA7NTRK1HTR3A | |
| SCHEMBL214090 | 0.73 | LCK (0.56) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL29840564 | 0.73 | LCK (0.56) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL19664232 | 0.73 | SMN1; SMN2 (0.44) | KDM4EALDH1A1MAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113387959-B | Synthesis method of thieno [3,2-c ] pyridine-6-carboxylic acid methyl ester | 烟台理工学院 | 2023-05-05 | — | — | CN | claimed |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-113387959-B | Synthesis method of thieno [3,2-c ] pyridine-6-carboxylic acid methyl ester | 烟台理工学院 | 2023-05-05 | — | — | CN | disclosed |
| EP-3696183-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | Prexton Therapeutics SA (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-20200171042-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | PREXTON THERAPEUTICS SA (CH) | 2020-06-04 | — | — | US | disclosed |
| US-10442818-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | PREXTON THERAPEUTICS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3502115-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | Prexton Therapeutics SA (CH) | 2019-06-26 | — | — | EP | disclosed |
| EP-3186257-B1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | PREXTON THERAPEUTICS SA (CH) | 2019-02-06 | — | — | EP | disclosed |
| US-10017521-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | PREXTON THERAPEUTICS SA (CH) | 2018-07-10 | — | — | US | disclosed |
| EP-1425286-A1 | SUBSTITUTED 7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039815-A2 | COMPOUNDS HAVING BOTH ALPHA7 NACHR AGONIST AND 5HT ANTAGONIST ACTIVITY FOR TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003022856-A1 | SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | LCK 1455/4885CHRNA7 1401/4885MAPK1 4496/4885 |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CHRNA7, CHRNA1, CHRNA6 | LCK 1588/4885CHRNA7 1/4885MAPK1 2413/4885 |
| US-20200171042-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | COMT, PARK7, SLC1A2 | LCK 2704/4885CHRNA7 44/4885MAPK1 1058/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | LCK 3015/4885CHRNA7 594/4885MAPK1 3403/4885 |
| US-10442818-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | GRM1, GRM2, GRM3 | LCK 1435/4885CHRNA7 36/4885MAPK1 456/4885 |
| US-10017521-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | GRM1, GRM2, GRM3 | LCK 1435/4885CHRNA7 36/4885MAPK1 456/4885 |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | LCK 50/4885CHRNA7 4769/4885MAPK1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.